302 related articles for article (PubMed ID: 26769075)
1. Axitinib for the treatment of metastatic renal cell carcinoma.
Parekh H; Griswold J; Rini B
Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
[TBL] [Abstract][Full Text] [Related]
2. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
3. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
5. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
6. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y; Shibasaki Y; Akaza H
Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
[TBL] [Abstract][Full Text] [Related]
7. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
8. Axitinib, a new therapeutic option in renal cell carcinoma.
Kessler ER; Bowles DW; Flaig TW; Lam ET; Jimeno A
Drugs Today (Barc); 2012 Oct; 48(10):633-44. PubMed ID: 23110259
[TBL] [Abstract][Full Text] [Related]
9. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
10. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
[TBL] [Abstract][Full Text] [Related]
11. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
12. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
Bracarda S; Castellano D; Procopio G; Sepúlveda JM; Sisani M; Verzoni E; Schmidinger M
Expert Opin Drug Saf; 2014 Apr; 13(4):497-510. PubMed ID: 24641566
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Carmichael C; Lau C; Josephson DY; Pal SK
Clin Adv Hematol Oncol; 2012 May; 10(5):307-14. PubMed ID: 22706540
[TBL] [Abstract][Full Text] [Related]
14. Axitinib (Inlyta) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928
[No Abstract] [Full Text] [Related]
15. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
16. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
[TBL] [Abstract][Full Text] [Related]
17. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
18. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
19. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
20. Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.
Larkin J; Fishman M; Wood L; Negrier S; Olivier K; Pyle L; Gorbunova V; Jonasch E; Andrews L; Staehler M
Am J Clin Oncol; 2014 Aug; 37(4):397-403. PubMed ID: 23357974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]